1. Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors
- Author
-
Lisova, Ksenia, Sergeev, Maxim, Evans-Axelsson, Susan, Stuparu, Andreea D, Beykan, Seval, Collins, Jeffrey, Jones, Jason, Lassmann, Michael, Herrmann, Ken, Perrin, David, Lee, Jason T, Slavik, Roger, and van Dam, R Michael
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Bioengineering ,Cancer ,Biotechnology ,Biomedical Imaging ,Neurosciences ,Urologic Diseases ,4.1 Discovery and preclinical testing of markers and technologies ,Good Health and Well Being ,Animals ,Boron Compounds ,Cell Line ,Tumor ,Fluorine Radioisotopes ,Lab-On-A-Chip Devices ,Mice ,Octreotide ,Positron Emission Tomography Computed Tomography ,Radioactive Tracers ,Radiochemistry ,Radiometry ,Receptors ,Somatostatin ,Tumor-targeting peptide ,Neuroendocrine tumors ,SSTR2 imaging ,Microfluidic radiochemistry ,Trifluoroborate ,Clinical translation ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
BackgroundPeptides labeled with positron-emitting isotopes are emerging as a versatile class of compounds for the development of highly specific, targeted imaging agents for diagnostic imaging via positron-emission tomography (PET) and for precision medicine via theranostic applications. Despite the success of peptides labeled with gallium-68 (for imaging) or lutetium-177 (for therapy) in the clinical management of patients with neuroendocrine tumors or prostate cancer, there are significant advantages of using fluorine-18 for imaging. Recent developments have greatly simplified such labeling: in particular, labeling of organotrifluoroborates via isotopic exchange can readily be performed in a single-step under aqueous conditions and without the need for HPLC purification. Though an automated synthesis has not yet been explored, microfluidic approaches have emerged for 18F-labeling with high speed, minimal reagents, and high molar activity compared to conventional approaches. As a proof-of-concept, we performed microfluidic labeling of an octreotate analog ([18F]AMBF3-TATE), a promising 18F-labeled analog that could compete with [68Ga]Ga-DOTATATE with the advantage of providing a greater number of patient doses per batch produced.MethodsBoth [18F]AMBF3-TATE and [68Ga]Ga-DOTATATE were labeled, the former by microscale methods adapted from manual labeling, and were imaged in mice bearing human SSTR2-overexpressing, rat SSTR2 wildtype, and SSTR2-negative xenografts. Furthermore, a dosimetry analysis was performed for [18F]AMBF3-TATE.ResultsThe micro-synthesis exhibited highly-repeatable performance with radiochemical conversion of 50 ± 6% (n = 15), overall decay-corrected radiochemical yield of 16 ± 1% (n = 5) in ~40 min, radiochemical purity >99%, and high molar activity. Preclinical imaging with [18F]AMBF3-TATE in SSTR2 tumor models correlated well with [68Ga]Ga-DOTATATE. The favorable biodistribution, with the highest tracer accumulation in the bladder followed distantly by gastrointestinal tissues, resulted in 1.26 × 10-2 mSv/MBq maximal estimated effective dose in human, a value lower than that reported for current clinical 18F- and 68Ga-labeled compounds.ConclusionsThe combination of novel chemical approaches to 18F-labeling and microdroplet radiochemistry have the potential to serve as a platform for greatly simplified development and production of 18F-labeled peptide tracers. Favorable preclinical imaging and dosimetry of [18F]AMBF3-TATE, combined with a convenient synthesis, validate this assertion and suggest strong potential for clinical translation.
- Published
- 2018